Riverside Partners’ Post

🚀 Stay Ahead in the Biotech & Pharma World with BiopharmaWatch.com! 🧬💼 Are you tracking the latest catalysts and key dates in the biotech and pharmaceutical sectors? Look no further! BiopharmaWatch.com offers a comprehensive FDA/PDUFA Catalyst Calendar that keeps you informed about upcoming clinical trials, regulatory events, and other key updates that can impact stock movements. 📈 From phase 1 to phase 3 readouts, our platform provides a daily updated tool to help you make informed decisions and stay ahead of the market. Here is the list of companies for next two weeks: argenx SE, Adverum Biotechnologies, Inc., 4D Molecular Therapeutics, Inc., Biora Therapeutics, Inc., Aligos Therapeutics, Inc., Ocular Therapeutix, Inc., Annexon Biosciences, Inc., Phathom Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Jaguar Health, Inc., Cellectar Biosciences, Inc., Clearside Biomedical, Inc., Longeveron Inc., Acumen Pharmaceuticals, Inc. 🔍 Key Features: Real-time updates on clinical trials and FDA approvals Detailed insights into market capital and volume Easy-to-navigate interface to track event types and stages Check out the latest events for July and start leveraging this powerful tool for your investment strategies! Visit BiopharmaWatch.com today and never miss a critical update again! #Biotech #Pharma #Investment #FDA #ClinicalTrials #StockMarket #InvestmentStrategies

Join us for an insightful keynote interview with Christophe Weber, President & CEO of Takeda, at the Global Pharma and Biotech Summit on Nov 5. Learn about his vision for the future of biopharma and healthcare in Asia and beyond! Learn more: https://bit.ly/4fTMY22

Here's how Bloomberg's Drug Profiles tool enhances competitive screening for pharma teams. 🎯 Elevate pipeline analysis with our comprehensive tracking of: ◾ Breakthrough designations ◾ Orphan indications ◾ Development phases Designed specifically for business development professionals who need to monitor global launches and partnership landscapes. 📊 Learn more about our Pharma and Biotech solutions here: https://bloom.bg/4fC7Bj6 #DrugDevelopment #PharmaIntelligence #Healthcare #corporations #BloombergTerminal

I am looking forward to this conversation about optimization of facility startups for next generation medicines and therapies this coming Monday!

2023 highlighted the vital role of partnerships in biopharma. As we blend the technical expertise of biotechs with the operational scale of big pharma, it’s clear that collaboration is the pathway to transforming patient care

Thoughts on this? >> Exclusive: Bain scoops up $3B for fourth life sciences fund after handful of M&A deals >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech

Here's how Bloomberg's Drug Profiles tool enhances competitive screening for pharma teams. 🎯 Elevate pipeline analysis with our comprehensive tracking of: ◾ Breakthrough designations ◾ Orphan indications ◾ Development phases Designed specifically for business development professionals who need to monitor global launches and partnership landscapes. 📊 Learn more about our Pharma and Biotech solutions here: https://bloom.bg/4eOcK66 #DrugDevelopment #PharmaIntelligence #Healthcare #corporations #BloombergTerminal

Why Summits is excited for our upcoming 23rd Pharma & BioTech PPM Conference being held in Boston, Ma (Oct. 16, 17, 18). Please contact me or Simona Marčeková to discuss attending or speaking at this event. #PPM #Pharma #Conference #ProjectManagement

Dive into our latest roundtable on the BIOSECURE Act's sweeping impacts on the biopharmaceutical world. How will it reshape innovation, safety, and the industry's path forward? Get insights straight from top industry experts!

Developing novel therapies to address unmet patient need is crucial in the biopharmaceutical industry. Bringing a new therapy to market requires an estimated $3.1 billion, with an 11% success rate from phase 1 through regulatory submission. A recent white paper by my IQVIA colleagues Markus Gores, William Harries Francesco Capuzzi, PhD delves into how clinical trial outcomes impact company valuations, especially for emerging biopharma companies with <$1 billion market capitalization. These companies are highly responsive to trial results, as their value is concentrated in their pipeline, often with just a single asset. The study highlights that EBP valuations are significantly more sensitive to clinical trial readouts, compared to big pharma companies. Explore more insights here: [Link to the white paper] #Biopharma #ClinicalTrials #CompanyValuations #Innovation #BigPharma #LifeSciences #Consulting #IQVIA #Valuation